Doctors prescribing ivermectin urged to 'follow up, document' results | Inquirer News

Doctors prescribing ivermectin urged to ‘follow up, document’ results

By: - Reporter / @JDTiloINQ
/ 01:29 PM May 04, 2021
ivermectin medicine against COVID-19

TO USE OR NOT TO USE A number of physicians swear by the effectiveness of ivermectin, an anti-parasitic drug commercially available only for veterinary use, as a treatment or preventive medicine against COVID-19. But the Philippines’ Food and Drug Administration maintains there are procedures to be followed, including clinical trials, before the drug could be allowed for distribution. —AFP FILE

MANILA, Philippines — An official from the Department of Science and Technology (DOST) urged doctors who are prescribing ivermectin to COVID-19 patients to make sure that they follow up and document the results.

The statement comes after some doctors began prescribing ivermectin despite its off-label status and warnings from some medical groups on its use against COVID-19.

ADVERTISEMENT

Dr. Jaime Montoya, executive director of the DOST-Philippine Council for Health Research and Development, told ANC’s “Headstart” that doctors who prescribed ivermectin to people are “responsible or accountable” for the person.

“We always have to remember that when you do that, it’s off-label, so you are responsible or accountable for that particular reason or indication. So, you have to follow up your patients closely and make sure that it is well documented,” he said.

FEATURED STORIES

He noted that while compassionate use of off-label products is a legal mechanism, it should only be for doctors and hospitals who applied for it, and “only for them, because it is not yet registered or approved in the country.”

According to Montoya, prescribing off-label products are “being done by doctors” based on “their better judgment,” but in general, “we want to recommend to all doctors – it has to be registered first by the FDA (Food and Drugs Administration) and based on sound evidence.”

Meanwhile, the official also stressed that the clinical trials on ivermectin use against COVID-19 will push through regardless of FDA approval.

“We will run the trial regardless [whether] there’s compassionate use or not because we are generating valuable information that will hopefully be used by the FDA in coming up with its decision,” he said.

Montoya also cited a World Health Organization (WHO) advisory stating that ivermectin can only be used to treat COVID-19 in clinical trials.

“So precisely, the WHO already said that to be used in a clinical trial setting. This is what we’re doing,” said Montoya.

“We are neutral, we are not for or against [using] ivermectin for COVID, what we’re doing is in fact to answer that question,” he added.

ADVERTISEMENT

RELATED STORIES:

WATCH: Defensor, Marcoleta lead ivermectin distribution in Quezon City

Ivermectin question sets off debate in PH medical community

JPV

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: clinical trials, COVID-19, DOST, Ivermectin, Jaime Montoya, WHO
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.